Vanguard Portfolio Management holds 8.47% of Organon (NYSE: OGN)
Filing Impact
Filing Sentiment
Form Type
SCHEDULE 13G
Rhea-AI Filing Summary
Vanguard Portfolio Management reports beneficial ownership of 22,052,559 shares of Organon & Co Common Stock (CUSIP 68622V106), representing 8.47% of the class. The filer states sole dispositive power for 22,052,559 shares and sole voting power for 206,523 shares.
The filing attributes holdings to Vanguard Portfolio Management LLC and listed affiliates and notes that the shares include positions held for Vanguard funds and managed accounts.
Positive
- None.
Negative
- None.
Key Figures
Beneficially owned shares: 22,052,559 shares
Percent of class: 8.47%
Sole voting power: 206,523 shares
+2 more
5 metrics
Beneficially owned shares
22,052,559 shares
Amount beneficially owned reported on Schedule 13G
Percent of class
8.47%
Percent of class reported on Schedule 13G
Sole voting power
206,523 shares
Number with sole power to vote reported in Item 4(i)
Sole dispositive power
22,052,559 shares
Number with sole power to dispose reported in Item 4(iii)
CUSIP
68622V106
Identifier for Organon & Co Common Stock on cover
Key Terms
beneficially owned, sole dispositive power, Schedule 13G, CUSIP
4 terms
beneficially owned regulatory
"This reflects the securities beneficially owned, or deemed to be beneficially owned"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
sole dispositive power regulatory
"Sole power to dispose or to direct the disposition of: 22052559"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.
Schedule 13G regulatory
"Item 1. | (a) | Name of issuer: Organon & Co"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
CUSIP other
"Title of class of securities: Common Stock (e) | CUSIP Number(s): 68622V106"
A CUSIP is a nine-character alphanumeric code that uniquely identifies a U.S. or Canadian financial security—such as a stock, bond, or fund share—like a Social Security number for an investment. It matters to investors because brokers, exchanges and record-keepers use the CUSIP to match trades, track ownership, settle transactions and pull accurate records, reducing errors and ensuring money and securities go to the right place.
FAQ
What stake does Vanguard hold in Organon (OGN)?
Vanguard holds 22,052,559 shares, or 8.47% of Organon Common Stock. The Schedule 13G lists the holdings as beneficially owned by Vanguard Portfolio Management LLC and affiliated investment vehicles.
What is the filing date and who signed the Schedule 13G for OGN?
The Schedule 13G was signed on 04/29/2026 by Ashley Grim, Head of Global Fund Administration, for Vanguard Portfolio Management. The document lists the issuer address and CUSIP for Organon.